T cell detection of a B-cell tropic virus infection: Newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display

PLoS Pathogens

Volumn 5, Issue 12, 2009, Pages

  Mackay, Laura K ^a   Long, Heather M ^a   Brooks, Jill M ^a   Taylor, Graham S ^a   Leung, Carol S ^a   Chen, Adrienne ^b   Wang, Fred ^b   Rickinson, Alan B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DOXYCYCLINE; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 3B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINE; CELL TRANSFORMATION; DOWN REGULATION; EPSTEIN BARR VIRUS; GENETIC TRANSFECTION; HALF LIFE TIME; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; NONHUMAN; PROTEIN SYNTHESIS; STEADY STATE; T LYMPHOCYTE; VIRUS GENE; VIRUS INFECTION; ANTIGEN PRESENTATION; EPSTEIN BARR VIRUS INFECTION; IMMUNOLOGY; TIME;

HUMAN HERPESVIRUS 4;

ANTIGEN PRESENTATION; ANTIGENS, VIRAL; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; T-LYMPHOCYTES; TIME FACTORS; VIRAL PROTEINS;

EID: 74549130997     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000699     Document Type: Article

References (47)

1. Esquivel F, Yewdell J, Bennink J (1992) RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J Exp Med 175: 163-168.
2. Goldberg AL, Rock KL (1992) Proteolysis, proteasomes and antigen presentation. Nature 357: 375-379.
3. Yewdell JW, Anton LC, Bennink JR (1996) Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol 157: 1823-1826.
4. Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, et al. (2003) Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18: 343-354.
5. Qian SB, Reits E, Neefjes J, Deslich JM, Bennink JR, et al. (2006) Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products. J Immunol 177: 227-233.
6. Reits EA, Vos JC, Gromme M, Neefjes J (2000) The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404: 774-778.
7. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, et al. (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404: 770-774.
8. Bulik S, Peters B, Holzhutter HG (2005) Quantifying the contribution of defective ribosomal products to antigen production: a model-based computational analysis. J Immunol 175: 7957-7964.
9. Vabulas RM, Hartl FU (2005) Protein synthesis upon acute nutrient restriction relies on proteasome function. Science 310: 1960-1963.
10. Eisenlohr LC, Huang L, Golovina TN (2007) Rethinking peptide supply to MHC class I molecules. Nat Rev Immunol 7: 403-410.
11. Yewdell JW, Nicchitta CV (2006) The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol 27: 368-373.
12. Donohue KB, Grant JM, Tewalt EF, Palmer DC, Theoret MR, et al. (2006) Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology 119: 63-73.
13. Khan S, de Giuli R, Schmidtke G, Bruns M, Buchmeier M, et al. (2001) Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J Immunol 167: 4801-4804.
14. Lechler R, Aichinger G, Lightstone L (1996) The endogenous pathway of MHC class II antigen presentation. Immunol Rev 151: 51-79.
15. Crotzer VL, Blum JS (2008) Cytosol to lysosome transport of intracellular antigens during immune surveillance. Traffic 9: 10-16.
16. Weiss S, Bogen B (1991) MHC class II-restricted presentation of intracellular antigen. Cell 64: 767-776.
17. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, et al. (2005) Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307: 593-596.
18. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, et al. (2003) Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 33: 1250-1259.
19. Zhou D, Li P, Lin Y, Lott JM, Hislop AD, et al. (2005) Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity 22: 571-581.
20. Taylor GS, Long HM, Haigh TA, Larsen M, Brooks J, et al. (2006) A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J Immunol 177: 3746-3756.
21. Rickinson AB, Kieff E (2006) Epstein-Barr virus. In: Fields B, Knipe D, Howley P, Chanock R, Melnick J, et al., eds. In Fields Virology. 5 ed. Philadelphia: Lippincott, Williams & Wilkins. pp 2655-2700.
22. Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
23. Chen A, Divisconte M, Jiang X, Quink C, Wang F (2005) Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro. J Virol 79: 4506-4509.
24. Tomkinson B, Kieff E (1992) Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol 66: 2893-2903.
25. Bhatia K, Raj A, Guitierrez MI, Judde JG, Spangler G, et al. (1996) Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas. Oncogene 13: 177-181.
26. Chen MR, Tsai CH, Wu FF, Kan SH, Yang CS, et al. (1999) The major immunogenic epitopes of Epstein-Barr virus (EBV) nuclear antigen 1 are encoded by sequence domains which vary among nasopharyngeal carcinoma biopsies and EBV-associated cell lines. J Gen Virol 80(Pt 2): 447-455.
27. Bornkamm GW, Berens C, Kuklik-Roos C, Bechet JM, Laux G, et al. (2005) Stringent doxycycline-dependent control of gene activities using an episomal one-vector system. Nucleic Acids Res 33: e137.
28. Leen A, Meij P, Redchenko I, Middeldorp J, Bloemena E, et al. (2001) Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol 75: 8649-8659.
29. Long HM, Haigh TA, Gudgeon NH, Leen AM, Tsang CW, et al. (2005) CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 79: 4896-4907.
30. Yin Y, Manoury B, Fahraeus R (2003) Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301: 1371-1374.
31. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG (1997) Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 94: 12616-12621.
32. Tellam J, Fogg MH, Rist M, Connolly G, Tscharke D, et al. (2007) Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J Exp Med 204: 525-532.
33. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, et al. (1999) Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189: 767-778.
34. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, et al. (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375: 685-688.
35. Lee SP, Brooks JM, Al-Jarrah H, Thomas WA, Haigh TA, et al. (2004) CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. J Exp Med 199: 1409-1420.
36. Tellam J, Connolly G, Green KJ, Miles JJ, Moss DJ, et al. (2004) Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med 199: 1421-1431.
37. Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, et al. (2004) Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 199: 459-470.
38. Blake N, Lee S, Redchenko I, Thomas W, Steven N, et al. (1997) Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7: 791-802.
39. Tellam J, Rist M, Connolly G, Webb N, Fazou C, et al. (2007) Translation efficiency of EBNA1 encoded by lymphocryptoviruses influences endogenous presentation of CD8+ T cell epitopes. Eur J Immunol 37: 328-337.
40. Tellam J, Smith C, Rist M, Webb N, Cooper L, et al. (2008) Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proc Natl Acad Sci U S A 105: 9319-9324.
41. Lanzavecchia A (1987) Antigen uptake and accumulation in antigen-specific B cells. Immunol Rev 99: 39-51.
42. Daskalogianni C, Apcher S, Candeias MM, Naski N, Calvo F, et al. (2008) GLY-ALA repeats induce position and substrate specific regulation of 26S proteasome-dependent partial processing. J Biol Chem.
43. Brooks JM, Colbert RA, Mear JP, Leese AM, Rickinson AB (1998) HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex. J Immunol 161: 5252-5259.
44. Gromme M, Uytdehaag FG, Janssen H, Calafat J, van Binnendijk RS, et al. (1999) Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad Sci U S A 96: 10326-10331.
45. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, et al. (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203: 1259-1271.
46. Midgley RS, Bell AI, McGeoch DJ, Rickinson AB (2003) Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes. J Virol 77: 11517-11530.
47. Grasser FA, Murray PG, Kremmer E, Klein K, Remberger K, et al. (1994) Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 84: 3792-3798.